Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in a phase 3 trial.The SELECT trial compared a weekly injection with GLP-1 agonist Wegovy (semaglutide) to a placebo in more than 17,000 overweight or obese patients who had underlying cardiovascular […]
